GU Cancers 2021 | UpFrontPSMA trial: 177Lu-PSMA-617 and docetaxel in mHNPC
Arun Azad, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, gives an overview on the Phase II UpFrontPSMA trial (NCT04343885), evaluating sequential 177Lu-PSMA-617 and docetaxel versus docetaxel in newly diagnosed metastatic hormone-naïve prostate cancer (mHNPC). Dr Azad also outlines results of the TheraP trial (NCT03392428) which investigated 177Lu-PSMA-617 versus cabazitaxel in progressive metastatic castration-resistant prostate cancer. The primary endpoint of the UpFrontPSMA trial is undetectable prostate-specific antigen (PSA). This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Dr Arun Azad, MBBS, PhD, FRACP, has participated in speaker bureaus with Astellas, Janssen, Novartis, Amgen, Ipsen, Bristol Myers Squibb, Merck Serono and Bayer, has received honoraria from Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Pfizer, Amgen, Noxopharm and Merck Sharpe Dome; has participated in scientific advisory boards with Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Merck Sharpe Dome, Amgen and Noxopharm; has received reimbursement for travel and accommodation from Astellas, Merck Serono, Amgen, Novartis, Janssen, Tolmar and Pfizer; and has received research funding from Astellas (investigator), Merck Serono (investigator), Astra Zeneca (investigator), Bristol Myers Squibb (institutional), Astra Zeneca (institutional), Aptevo Therapeutics (institutional), Glaxo Smith Kline (institutional), Pfizer (institutional), MedImmune (institutional), Astellas (institutional), SYNthorx (institutional), Bionomics (institutional), Sanofi Aventis (institutional), Novartis (institutional) and Ipsen (institutional).
